2026-05618RuleWallet

DEA Bans Mind-Bending 3-MeO-PCP in Schedule I Crackdown

Published Date: 3/23/2026

Rule

Summary

Starting April 22, 2026, the DEA is putting 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it’s now officially a highly controlled substance with strict rules. This affects anyone who makes, sells, studies, or even possesses 3-MeO-PCP, who will face serious legal consequences. This move helps the U.S. follow international drug laws and keeps communities safer.

Analyzed Economic Effects

5 provisions identified: 1 benefits, 4 costs, 0 mixed.

3‑MeO‑PCP Placed Into Schedule I

Starting April 22, 2026, the Drug Enforcement Administration places 3-methoxyphencyclidine (3-MeO-PCP) in Schedule I of the Controlled Substances Act. That means possession, manufacture, distribution, importation, exportation, or other handling of 3-MeO-PCP is subject to the strict criminal, civil, and administrative penalties that apply to Schedule I substances.

DEA Registration Required to Handle 3‑MeO‑PCP

If you handle 3-MeO-PCP (manufacture, distribute, research with, import, export, or possess), you must register with DEA under 21 U.S.C. 822, 823, 957, and 958 and follow 21 CFR parts 1301 and 1312. Any person who currently handles 3-MeO-PCP and is not registered must submit an application and may not continue to handle it unless DEA approves the registration before the effective date.

Strict Compliance Rules for Registrants

DEA registrants handling 3-MeO-PCP must follow Schedule I controls including security requirements, labeling and packaging rules, quotas for manufacture, and recordkeeping and reporting. Registrants must take an initial inventory on the date they first handle controlled substances and thereafter inventory all controlled substances (including 3-MeO-PCP) every two years, and must comply with disposal rules and order form, import/export, and quota requirements.

Research Allowed but Requires Schedule I Registration

The final rule states that placing 3-MeO-PCP in Schedule I does not preclude research, but researchers must comply with DEA's Schedule I registration processes and requirements to conduct research legally. Those who wish to study 3-MeO-PCP must follow the DEA registration process for Schedule I substances before engaging in research.

DEA Says Limited Small‑Entity Economic Impact

DEA certifies under the Regulatory Flexibility Act that this final rule will not have a significant economic impact on a substantial number of small entities. The agency notes there appear to be no legitimate marketed sources for 3-MeO-PCP in the U.S., though legitimate suppliers sell it for scientific research, and there is no evidence of significant diversion from legitimate suppliers.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Rule Effective
3/23/2026
4/22/2026

Department and Agencies

Department
Independent Agency
Agency
Justice Department
Drug Enforcement Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in